Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

The Worldwide Metastatic Cancer Drug Industry is Expected to Reach $68.3 Billion by 2028

Published

on

Dublin, June 30, 2022 (GLOBE NEWSWIRE) — The “Global Metastatic Cancer Drug Market Forecast to 2028 – COVID-19 Impact and Global Analysis by Cancer Type, Route of Administration, Drug Class, Product, and End User” report has been added to ResearchAndMarkets.com’s offering.

The metastatic cancer drug market size is projected to reach US$ 68,349.54 million by 2028 from US$ 51,157.97 million in 2021. It is expected to grow at a CAGR of 4.2% from 2021 to 2028. The report highlights trends prevailing in the market and factors driving the metastatic cancer drug market growth.

The growth in the metastatic cancer drug market is attributed to the increasing prevalence of metastatic cancer across the world and rising government initiatives to support research and developments in cancer treatment. However, the high cost of oncology drugs restricts the market.

Metastatic cancer is defined as an advanced cancer stage that spreads to the other body parts, and the drugs used for the treatment of advanced-stage cancer are known as metastatic cancer drugs. These drugs are used through various therapies, such as chemotherapy, immunotherapy, and targeted therapy.

Governments of various countries are introducing missions and programs for quick and effective cancer treatment. In 2016, the US Government launched the Cancer Moonshot with three ambitious goals: To accelerate scientific cancer-related discovery, foster greater collaboration, and improve data sharing. The cancer patient community and medical researchers responded with tremendous energy and ingenuity to this campaign.

On February 2, 2022, the Cancer Moonshot project was relaunched by highlighting new goals of reducing the death rate of cancer by at least 50% over the next 25 years, improving the experience of people and their families living with and surviving cancer, and putting an end to cancer through these efforts. By focusing on the areas of cancer research and encouraging new investments that are most likely to benefit patients, the Cancer Moonshot has brought together a large community of investigators and clinicians dedicated to expediting research to improve the lives of patients.

In 2020, 2.7 million people in the European Union were diagnosed with the disease, and another 1.3 million people lost their lives to it. The EU has been working to tackle cancer for decades and its actions, for example tobacco control and protection from hazardous substances, have saved and prolonged lives. Europe’s Beating Cancer Plan is the EU’s response to the need for cancer treatment. It reflects a political commitment to leave no stone unturned to take action against cancer.

Mobilizing the collective power of the EU to drive change for the benefit of the citizens, the Cancer Plan contains concrete, ambitious actions that will support, coordinate and complement Member States’ efforts to reduce the suffering caused by cancer. Over the coming years, it will focus on research and innovation, tap into the process of digitalization and offer new technologies, and mobilize financial instruments to support the Member States.

The European Medicines Agency introduced and authorized a drug named Trodelvy that exhibits greater benefits than its risks. In January 2021, AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s Enhertu (trastuzumab deruxtecan) were granted conditional approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens. In Europe, over 531,000 breast cancer cases in women are diagnosed per year, with approximately 1 in 5 patients being HER2-positive. The impact of the disease is significant, with breast cancer responsible for more than 141,000 deaths annually in Europe.

In January 2022, AbbVie announced that the US FDA granted Breakthrough Therapy Designation (BTD) to investigate the telisotuzumab vedotin (Teliso-V) for the treatment of patients with advanced/metastatic epidermal growth factor receptor (EGFR) wild type, nonsquamous non-small cell lung cancer (NSCLC) with high levels of c-Met overexpression whose disease has progressed on or after platinum-based therapy.

Key Topics Covered:

1. Introduction

2. Metastatic Cancer Drugs Market – Key Takeaways

3. Research Methodology

4. Global Metastatic Cancer Drugs Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America – PEST Analysis
4.2.2 Europe – PEST Analysis
4.2.3 Asia Pacific – PEST Analysis
4.2.4 South & Central America – PEST Analysis
4.2.5 Middle East & Africa – PEST Analysis
4.3 Expert Opinion

5. Metastatic Cancer Drugs Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 High Prevalence of Metastatic Cancer
5.1.2 Government Initiatives to Support Developments in Cancer Treatment
5.2 Market Restraints
5.2.1 High Cost of Oncology Drugs
5.3 Market Opportunities
5.3.1 Investments in Artificial Intelligence for Oncology Drug Development
5.4 Future Trends
5.4.1 Increase in Launch of Metastatic Cancer Drugs
5.5 Impact analysis

6. Metastatic Cancer Drugs Market – Global Analysis
6.1 Global Metastatic Cancer Drugs Market Revenue Forecast and Analysis
6.1.1 Global Metastatic Cancer Drugs Market, By Geography – Forecast and Analysis
6.1.2 Global Metastatic Cancer Drugs Market – Market Potential Analysis, By Region
6.2 Company Analysis
6.2.1 Market Positioning of Key Players
6.2.2 Comparative Company Analysis
6.2.3 Growth Strategy Analysis
6.2.4 Performance of Key Players
6.2.4.1 Celgene Corporation
6.2.4.2 Novartis AG

7. Metastatic Cancer Drug Market Analysis – By Cancer Type
7.1 Overview
7.2 Metastatic Cancer Drug Market Revenue Share, by Cancer Type (2021 and 2028)
7.3 Breast Cancer
7.3.1 Overview
7.3.2 Breast Cancer: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Lung Cancer
7.4.1 Overview
7.4.2 Lung Cancer: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
7.5 Liver Cancer
7.5.1 Overview
7.5.2 Liver Cancer: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
7.6 Hematological Cancer
7.6.1 Overview
7.6.2 Hematological Cancer: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
7.7 Brain Cancer
7.7.1 Overview
7.7.2 Brain Cancer: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
7.8 Prostate Cancer
7.8.1 Overview
7.8.2 Prostate Cancer: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
7.9 Pancreatic Cancer
7.9.1 Overview
7.9.2 Pancreatic Cancer: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
7.10 Others
7.10.1 Overview
7.10.2 Others: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

8. Metastatic Cancer Drug Market – By Route of Administration
8.1 Overview
8.2 Metastatic Cancer Drug Market, by Route of Administration, 2021 and 2028 (%)
8.3 Intravenous
8.3.1 Overview
8.3.2 Intravenous: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Intramuscular
8.4.1 Overview
8.4.2 Intramuscular: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
8.5 Oral
8.5.1 Overview
8.5.2 Oral: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

9. Metastatic Cancer Drug Market – By Drug Class
9.1 Overview
9.2 Metastatic Cancer Drug Market, by Drug Class, 2021 and 2028 (%)
9.3 HER2 Inhibitors
9.3.1 Overview
9.3.2 HER2 Inhibitors: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
9.4 Immune Checkpoints Inhibitors
9.4.1 Overview
9.4.2 Immune Checkpoints Inhibitors: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
9.5 PARP Inhibitors
9.5.1 Overview
9.5.2 PARP Inhibitors: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
9.6 Kinase Inhibitors
9.6.1 Overview
9.6.2 Kinase Inhibitors: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
9.7 Others
9.7.1 Overview
9.7.2 Others: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

10. Metastatic Cancer Drug Market – By Product
10.1 Overview
10.2 Metastatic Cancer Drug Market, by Product, 2021 and 2028 (%)
10.3 Branded
10.3.1 Overview
10.3.2 Branded: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
10.4 Generics and Biosimilars
10.4.1 Overview
10.4.2 Generics and Biosimilars: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

11. Metastatic Cancer Drug Market – By End User
11.1 Overview
11.2 Metastatic Cancer Drug Market, by End User, 2021 and 2028 (%)
11.3 Hospital
11.3.1 Overview
11.3.2 Hospitals: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
11.4 Specialty Clinic
11.4.1 Overview
11.4.2 Specialty Clinics: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)
11.5 Others
11.5.1 Overview
11.5.2 Others: Metastatic Cancer Drug Market – Revenue and Forecast to 2028 (US$ Million)

12. Metastatic Cancer Drugs Market – Regional Analysis

13. Impact of COVID-19 Pandemic on Global Metastatic Cancer Drugs Market
13.1 North America: Impact Assessment of COVID-19 Pandemic
13.2 Europe: Impact Assessment of COVID-19 Pandemic
13.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
13.4 Middle East & Africa: Impact Assessment of COVID-19 Pandemic
13.5 South and Central America: Impact Assessment of COVID-19 Pandemic

14. Metastatic Cancer Drug Market – Industry Landscape
14.1 Overview
14.2 Growth Strategies in the Metastatic Cancer Drug Market, 2021-2028
14.3 Inorganic Developments
14.3.1 Overview
14.4 Organic Growth Strategies
14.4.1 Overview

15. Company Profiles
15.1 AbbVie Inc.
15.1.1 Key Facts
15.1.2 Business Description
15.1.3 Products and Services
15.1.4 Financial Overview
15.1.5 SWOT Analysis
15.1.6 Key Developments
15.2 Amgen Inc.
15.2.1 Key Facts
15.2.2 Business Description
15.2.3 Products and Services
15.2.4 Financial Overview
15.2.5 SWOT Analysis
15.2.6 Key Developments
15.3 Bristol-Myers Squibb Company
15.3.1 Key Facts
15.3.2 Business Description
15.3.3 Products and Services
15.3.4 Financial Overview
15.3.5 SWOT Analysis
15.3.6 Key Developments
15.4 F. HOFFMANN-LA ROCHE LTD.
15.4.1 Key Facts
15.4.2 Business Description
15.4.3 Products and Services
15.4.4 Financial Overview
15.4.5 SWOT Analysis
15.4.6 Key Developments
15.5 Novartis AG
15.5.1 Key Facts
15.5.2 Business Description
15.5.3 Products and Services
15.5.4 Financial Overview
15.5.5 SWOT Analysis
15.5.6 Key Developments
15.6 Astrazeneca
15.6.1 Key Facts
15.6.2 Business Description
15.6.3 Products and Services
15.6.4 Financial Overview
15.6.5 SWOT Analysis
15.6.6 Key Developments
15.7 Eli Lilly and Company.
15.7.1 Key Facts
15.7.2 Business Description
15.7.3 Products and Services
15.7.4 Financial Overview
15.7.5 SWOT Analysis
15.7.6 Key Developments
15.8 MERCK KGaA
15.8.1 Key Facts
15.8.2 Business Description
15.8.3 Products and Services
15.8.4 Financial Overview
15.8.5 SWOT Analysis
15.8.6 Key Developments
15.9 Pfizer Inc. (Arena Pharmaceutical GmbH)
15.9.1 Key Facts
15.9.2 Business Description
15.9.3 Products and Services
15.9.4 Financial Overview
15.9.5 SWOT Analysis
15.9.6 Key Developments
15.10 Johnson and Johnson Services, Inc.
15.10.1 Key Facts
15.10.2 Business Description
15.10.3 Products and Services
15.10.4 Financial Overview
15.10.5 SWOT Analysis
15.10.6 Key Developments

16. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/h4sw5y

Attachment


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

Military Cybersecurity Market to Reach $68.5 Billion, Globally, by 2033 at 15.4% CAGR: Allied Market Research

Published

on

military-cybersecurity-market-to-reach-$685-billion,-globally,-by-2033-at-15.4%-cagr:-allied-market-research

PORTLAND, Ore., May 20, 2024 /PRNewswire/ — Allied Market Research published a report, titled, “Military Cybersecurity Market by Type (Endpoint Security Solutions, Network Security Solutions, Content Security Solutions), Deployment (On-Premises, Cloud), and Solution (Threat Intelligence and Response Management, Identity and Access Management, Data Loss Prevention Management, Security and Vulnerability Management, Unified Threat Management, Enterprise Risk and Compliance, Managed Security, Others): Global Opportunity Analysis and Industry Forecast, 2024-2033”. According to the report, the military cybersecurity market was valued at $15.7 billion in 2023, and is estimated to reach $68.5 billion by 2033, growing at a CAGR of 15.4% from 2024 to 2033.

The global military cybersecurity market is driven by factors such as growing demand for end-point security solutions and surge in cyber-attacks which are increasing need for military cybersecurity.
Prime Determinants of Growth
The global military cybersecurity market is driven by factors such as an increase in demand for defense IT expenditure. Adoption of IoT in cyber security technology provides lucrative growth opportunities. On the other hand, limited awareness related to cybersecurity is projected to hinder market growth.
Request Sample of the Report on Military Cybersecurity Market Forecast 2033
https://www.alliedmarketresearch.com/request-sample/A323349
(We are providing Military Cybersecurity Industry report as per your research requirement, including the Latest Industry Insight’s Evolution, Potential and Russia-Ukraine War Impact Analysis)
123 – Tables63 – Charts378 – PagesReport coverage & details:
Report Coverage 
Details 
Forecast Period
2023–2033
Base Year
2023
Market Size in 2023
$15.7 Billion
Market Size in 2033
$68.5 Billion
CAGR
15.4 %
No. of Pages in Report
324
Segments covered
Type, Deployment, Solution and Region.
Drivers 
Increase in demand for defense IT expenditure to drive the market growth.
Opportunities
Adoption of IoT in Cyber Security Technology
Restraints
Limited awareness related to cybersecurity is restricting the market growth
Procure Complete Report (323 Pages PDF with Insights, Charts, Tables, and Figures)https://www.alliedmarketresearch.com/checkout-final/military-cybersecurity-market-A323349
The endpoint security solutions segment to maintain its leadership status throughout the forecast period
Based on type, the endpoint security solutions segment held the highest market share in 2023, accounting for more than two-fifths of the global military cybersecurity market revenue and is estimated to maintain its leadership status throughout the forecast period.
Endpoint security solutions are undergoing continuous evolution to combat the ever-changing landscape of cybersecurity threats. One prominent trend is the widespread adoption of Endpoint Detection and Response (EDR) solutions. EDR offers real-time monitoring of endpoint activities, allowing for swift detection and response to advanced threats.
The on-premises segment to maintain its leadership status throughout the forecast period
Based on deployment, the on-premises segment held the highest market share in 2023, accounting for more than half of the global military cybersecurity market and is estimated to maintain its leadership status throughout the forecast period. However, the cloud segment is projected to manifest the highest CAGR of 15.88% from 2023 to 2033. Moreover, cloud computing offers advanced security features and capabilities that strengthen military cybersecurity defense. Leading cloud service providers invest heavily in robust security measures, such as encryption, identity and access management, and threat detection, to protect data and applications hosted in the cloud.
The identity and access management segment to maintain its leadership status throughout the forecast period
Based on solution, the identity and access management segment held the highest market share in 2023, accounting for nearly one-fifth of the global military cybersecurity market and is estimated to maintain its leadership status throughout the forecast period. Moreover,
Identity and access management (IAM) plays a crucial role in military cybersecurity by ensuring that only authorized personnel can access sensitive information and critical systems. IAM encompasses processes, policies, and technologies designed to manage digital identities, control access to resources, and protect against unauthorized access and insider threats.
North America to maintain its dominance by 2033
Based on region, North America held the highest market share in terms of revenue in 2023, accounting for more than half of the global military cybersecurity market revenue and is likely to dominate the market during the forecast period. The advancements in sensor technology, artificial intelligence, and communication systems have contributed to the evolution of military cybersecurity, enabling greater autonomy, flexibility, and effectiveness in engaging both stationary and moving targets with reduced collateral damage.
To Talk With Our Industry Expert @ https://www.alliedmarketresearch.com/connect-to-analyst/A323349
Leading Market Players:
AT&TBAE SystemsBoeingCisco Systems, Inc.DXC Technology CompanyEclecticIQ B.V.IBM CorporationIntel CorporationLockheed Martin CorporationNorthrop Grumman CorporationPrivacera, Inc.SentineIOneSecureworks, Inc.Thales GroupThe report provides a detailed analysis of these key players in the global military cybersecurity market. These players have adopted different strategies such as new product launches, collaborations, expansion, joint ventures, agreements, and others to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.
Browse More Trending Reports
Aerospace Adhesives Market Size, Share, Competitive Landscape and Trend Analysis Report by Technology, by Resin Type, by Function, by End-user : Global Opportunity Analysis and Industry Forecast, 2023-2032
Aircraft Gearbox Market Size, Share, Competitive Landscape and Trend Analysis Report by Application, by Component, by End Use, by Sales Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031
Aircraft Maintenance Market Size, Share, Competitive Landscape and Trend Analysis Report by Maintenance Type, by Aircraft Type and by End-Use : Global Opportunity Analysis and Industry Forecast, 2023-2032
Airport Ground Handling Market Size, Share, Competitive Landscape and Trend Analysis Report by Service, by Airport, by Provider : Global Opportunity Analysis and Industry Forecast, 2023-2032
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact:
David Correa1209 Orange Street,Corporation Trust Center,Wilmington, New Castle,Delaware 19801 USA.USA/Canada (Toll Free):+1-800-792-5285UK: +44-845-528-1300Hong Kong: +852-301-84916India (Pune): +91-20-66346060Fax: [email protected] Web: www.alliedmarketresearch.com AMR Resource Center: https://www.alliedmarketresearch.com/resource-center
Logo: https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg 
 

View original content:https://www.prnewswire.co.uk/news-releases/military-cybersecurity-market-to-reach-68-5-billion-globally-by-2033-at-15-4-cagr-allied-market-research-302149843.html

Continue Reading

Artificial Intelligence

Dahua Network Camera Series Obtains CC EAL 3+ Certificate

Published

on

dahua-network-camera-series-obtains-cc-eal-3+-certificate

HANGZHOU, China, May 20, 2024 /PRNewswire/ — Dahua Technology, a world-leading video-centric AIoT solution and service provider, is proud to announce that its network cameras have successfully obtained Common Criteria (CC) EAL 3+ certificate. This achievement demonstrates Dahua’s dedication to delivering secure and reliable solutions that comply with the industry’s highest information security standards and best practices.

The Evaluation Assurance Level (EAL) 3+ certificate, issued by the Common Criteria for Information Technology Security Evaluation (CC), represents a widely used industry standard for evaluating the security features of IT products and systems. It has been recognized by 31 member countries of the Common Criteria Recognition Arrangement (CCRA) organization, which consists of the United States, Germany, the United Kingdom, the Netherlands, Japan, etc.
As the most authoritative and influential information security standard worldwide, obtaining the CC EAL 3+ certificate verifies Dahua’s robust measures against potential security threats throughout the entire R&D, production, and delivery processes. This also signifies that Dahua’s information security management capabilities meet internationally recognized industry standards.
The certification process involves comprehensive testing and evaluation of Dahua’s development environment, production environment, supply chain, vulnerability assessment, personnel security, as well as many other aspects. The security evaluation is completed by SGS Brightsight, a globally renowned security assessment laboratory in the Netherlands and approved by the Netherlands Scheme for Certification in the Area of IT Security (NSCIB).
“At Dahua, we prioritize the security needs and trust of our customers above all else. With the addition of CC EAL 3+ certificate, customers can be confident that they are investing in a secure and reliable solution that delivers unparalleled peace of mind, safeguarding their assets and ensuring uninterrupted operations,” stated Max Xiang, IPC Product Director at Dahua Technology.
Dahua always follows best industry practices and maintains the highest standards of security across all aspects of the company’s operations. In addition to product security and privacy protection, Dahua implements strict quality control measures to strengthen supply chain security. Forging ahead, Dahua will remain dedicated to advancing the security industry through innovative and secure solutions, further enhancing its cybersecurity and data protection capabilities, and working with industry partners to build a trustworthy AIoT environment.
For more in-depth insights into Dahua’s cybersecurity practices, please visit www. dahuasecurity.com 
Photo – https://mma.prnewswire.com/media/2416612/image_1.jpgLogo –  https://mma.prnewswire.com/media/2074657/Dahua_LOGO_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/dahua-network-camera-series-obtains-cc-eal-3-certificate-302149811.html

Continue Reading

Artificial Intelligence

AGI to Debut at COMPUTEX 2024

Published

on

agi-to-debut-at-computex-2024

TAIPEI, May 20, 2024 /PRNewswire/ — AGI Technology, a pioneering provider of high-performance storage solutions from Taiwan, will make its inaugural appearance at COMPUTEX 2024. This grant event will take place from June 4 to June 7 at the Taipei Nangang Exhibition Center, where AGI will be showcasing its latest innovations at Booth #J0218.

Event DetailsDate: June 4 – 7, 2024Time: 9:30 a.m. – 5:30 p.m.Location: Taipei Nangang Exhibition Center, Hall 1Booth: #J0218
AGI will present cutting-edge technology across three main themes:
Spotlight Innovations
– Supreme Pro TF138 2TB microSD: The world’s first 2TB microSD card, exclusively produced by AGI, sets a new standard in mass production and storage capacity.
– TURBOJET RGB DDR5 Series: This DDR5 series, featuring RGB lighting and a heat sink for overclocking, delivers exceptional performance.
– EDM38 Portable SSD for Mobile: A portable SSD with MagSafe-compatible magnetic attachment that offers lightweight portability.
Ultra-Spec Solutions
– SATA 8TB SSD: This 8TB SATA SSD is pushing the limits of consumer-grade storage, setting a new benchmark for capacity.
– PCIe 16TB SSD: A 16TB PCIe SSD that leads in the HMB domain, providing unmatched performance.
Customization Zone
AGI will showcase tailored storage solutions that meet unique customer needs.
We welcome you to visit AGI at Booth #J0218 to discover these innovations and explore collaboration opportunities.
About AGI
AGI is a leading provider of high-performance storage solutions, offering a range of innovative products that meet the evolving needs of its customers. With a commitment to delivering cutting-edge storage capacities and superior performance, AGI empowers its customers to achieve exceptional digital experiences.
Contact Information
Sales [email protected]+8862-27937256www.agi-gear.com 
Photo – https://mma.prnewswire.com/media/2414525/BANNER_COMPUTEX10.jpg

View original content:https://www.prnewswire.co.uk/news-releases/agi-to-debut-at-computex-2024-302147537.html

Continue Reading

Trending